United Therapeutics CEO Martine Rothblatt Sells $4.79M in Stock via 10b5-1 Plan
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📊 Insider Transaction Report: United Therapeutics Corp ($UTHR)
Insider: Martine A. Rothblatt (Chairperson & CEO) Transaction Date: September 14, 2026 Action: Option Exercise & Sale (10b5-1 Trading Plan) Shares Sold: 9,500 @ avg ~$504.12 Total Value: ~$4.79M Remaining Direct/Indirect Holdings: 668,728 shares across direct holdings and trusts
Comprehensive Analysis
Insider Transaction Overview
On September 14, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp ($UTHR), executed an option exercise and sold a total of 9,500 shares of common stock under a pre-established Rule 10b5-1 trading plan.
Key Details:
- Derivative Transaction: Exercised stock options covering 9,500 shares at an exercise price of $117.76 per share.
- Sales Transactions: Sold the underlying 9,500 shares in multiple tranches at weighted average prices ranging from $502.15 to $506.48, generating gross proceeds of approximately $4.79 million (blended average price of ~$504.12 per share).
- Trading Plan: Executed pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.
- Post-Transaction Holdings: The reporting person maintains significant beneficial ownership, directly and through family trusts, holding over 660,000 shares of common stock alongside 442,410 remaining derivative options.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.